DNA-Based Zika Vaccine Shows Protection Against Infection

Share this content:
DNA-Based Zika Vaccine Shows Protection Against Infection
DNA-Based Zika Vaccine Shows Protection Against Infection

THURSDAY, Nov. 10, 2016 (HealthDay News) -- An experimental Zika vaccine shows promise, according to research published online Nov. 10 in npj Vaccines.

In animals infected with Zika virus, the synthetic DNA-based vaccine was 100 percent effective in protecting against infection, brain damage, and death, the researchers found. They observed robust antigen-specific antibody and T-cell responses that neutralized the virus.

The vaccine is being tested in two human clinical trials, with results from one study expected to be reported by year's end, the study authors noted.

"Our results support the critical importance of immune responses for both preventing infection as well as ameliorating disease caused by the Zika virus," lead author David Weiner, Ph.D., executive vice president and director of the Vaccine Center at The Wistar Institute in Philadelphia, said in an institute news release. "As the threat of Zika continues, these results provide insight into a new aspect of the possibly protective ability of such a vaccine as a preventative approach for Zika infection."

Weiner disclosed funding from Inovio Pharmaceuticals and GeneOne Life Science.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

900 Steps Tied to Functional Decline in Hospitalized Seniors

<900 Steps Tied to Functional Decline in Hospitalized ...

Walking <900 steps/day linked to hospitalization-associated functional decline

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Does not prevent venous thromboembolism after knee arthroplasty, casting of lower leg

ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

ASH: Lower Rate of Sickle Cell Pain Crises ...

Lower rate of crises per year; longer median time to first, second crises with high-dose therapy

is free, fast, and customized just for you!

Already a member?

Sign In Now »